

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Obecabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia [ID6347]

Final Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
Autolus (obecabtagene autoleucel)	All Wales Therapeutics and Toxicology
	Centre
Patient/carer groups	Allied Health Professionals Federation
African Caribbean Leukaemia Trust	Board of Community Health Councils in
Anthony Nolan	Wales
Black Health Agency for Equality	British National Formulary
Blood Cancer UK	Care Quality Commission
Cancer 52	Department of Health, Social Services
Cancer Black Care	and Public Safety for Northern Ireland
Cancer Equality	Healthcare Improvement Scotland Heartist Information Commission
Chronic Lymphocytic Leukaemia	 Hospital Information Services – Jehovah's Witnesses
Support Association	
DKMS Helen Bellagen Concer Charity	 Medicines and Healthcare products Regulatory Agency
Helen Rollason Cancer Charity Independent Cancer Patients Voice	 National Association of Primary Care
Independent Cancer Patients VoiceKevin Kararwa Leukaemia Trust	National Pharmacy Association
	NHS Blood and Transplant
Leukaemia Cancer Society Leukaemia Care	NHS Confederation
Leukaemia UK	Scottish Medicines Consortium
Macmillan Cancer Support	Welsh Government
Maggie's Centres	Welsh Health Specialised Services
Marie Curie	Committee
South Asian Health Foundation	
Specialised Healthcare Alliance	Comparator companies
Tenovus Cancer Care	 AAH Pharmaceuticals (dasatinib,
WMUK	imatinib)
	Accord UK (cytarabine, filgrastim,
Healthcare professional groups	fludarabine, imatinib, pegfilgrastim
Association of Anaesthetists	Amarox (imatinib) Amarox (inline to the control of the co
Association of Cancer Physicians	Amgen (blinatumomab, filgrastim, pagfilgrastim)
Association of Surgeons of Great	pegfilgrastim)
Britain and Ireland	Aurobindo (Milpharm) (imatinib) Chugai Pharma LIK Ltd (langgraptim)
British Blood Transfusion Society	Chugai Pharma UK Ltd (lenograstim)Cipla EU (imatinib)
British Geriatrics Society	Dr. Reddy's Laboratories (imatinib)
British Institute of Radiology	DI. Neddy's Laboratories (Illiatinib)

Final stakeholder list for the evaluation of obecabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia [ID6347]



Provisional Consultees Provisional Commentators (no right to submit or appeal) **British Oncology Pharmacy** Hospira UK (cytarabine) Association Incyte Biosciences UK (ponatinib) British Psychosocial Oncology Society Mylan (dasatinib) British Society for Haematology Napp Pharmaceuticals (pegfilgrastim) British Society of Blood and Marrow Novartis (imatinib, tisagenlecleucel) Transplantation and Cellular Therapy Pfizer (cytarabine, filgrastim, idarubicin, **British Transplantation Society** inotuzumab ozogamicin) British Society of Interventional Sandoz (dasatinib, filgrastim, imatinib, Radiology pegfilgrastim) Cancer Research UK Sanofi (fludarabine) NHS Blood and Transplant Teva UK (dasatinib, fludarabine, Royal College of General Practitioners lipegfilgrastim) Viatris UK Healthcare (dasatinib) Royal College of Nursing Royal College of Pathologists Zentiva (dasatinib) Royal College of Physicians Relevant research groups Royal College of Radiologists Cochrane Haematological Malignancies Royal Pharmaceutical Society Group Royal Society of Medicine Genomics England Society and College of Radiographers Institute of Cancer Research **UK Clinical Pharmacy Association** Leukaemia Busters **UK Oncology Nursing Society** Lymphoma Research Trust MRC Clinical Trials Unit Others National Institute for Health Research Department of Health and Social Care **NHS** England Associated Public Health groups **Public Health Wales** UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.


Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Final stakeholder list for the evaluation of obecabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia [ID6347]

Issue date: September 2024



Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.